Answers are grounded in this paper and cite their sources.
The design of MAPs needs to be determined based on what properties would be effective for the target diseases and purposes. In addition, in preclinical studies, it is necessary to consider not only the novelty of the formulations but also the feasibility of clinical application. Currently, clinical studies of microneedles loaded with various drugs and vaccines are in progress. When the regulation of pharmaceutical microneedles is established and more clinical studies are published, more drugs will be developed as microneedle products and clinical research will proceed. With these considerations, the microneedle array patch will be a better option for drug delivery.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: